By: Tiffani Bouchard, CCS Managing JW and JZ Modifiers When Billing Single-Dose Drugs Managing JW and JZ modifiers when billing single-dose drugs can be challenging. As you may know, the Medicare Program has been requiring the use of the JW modifier (Drug amount discarded and not administered to any...
By: Pamela McIntyre, CRNI, IgCN, OCN, and VA-BC Maximizing Efficiency in Ambulatory Infusion Centers When it comes to maximizing efficiency in ambulatory infusion centers, one of the most frequently asked questions infusion center managers have is how to determine the appropriate ratio of nurses to patients at their infusion...
By: Michael Rigas, Pharm.D., FNHIA Biosimilars are also known as follow-on biologics or subsequent-entry biologics. They are FDA-approved copies of the original “innovator” drug product that are allowed to be licensed and approved by the FDA once the innovator product’s patent expires. The Biologics Price and Competition Act (BPCA)...
By: Ty Bello, BS, RCC The objective of this article is to provide information with application so you, as an Independent Ambulatory Infusion Center, can either begin the sales journey or accelerate the existing sales process in your business. So regardless of whether or not you have a sales...
By: Kay Coulter, RN, CRNI, VA-BC In the insurance industry there’s a saying about how you don’t know you’re facing litigation until it’s too late. Ambulatory Infusion Center providers can tell you risk management is key to protecting patients from harm and staff from lawsuits. IV Therapy Practice Pearls...
What’s behind the recent surge of investments into the infusion industry? The ambulatory infusion center (AIC) industry has seen a significant surge in investment in recent years. This trend is driven by a number of factors, including an aging population, an increase in chronic diseases, and a shift towards...